Литература на тему: «Клиника и терапия депрессий при шизофрении»


  1. Авруцкий Г. Я. Некоторые общие закономерности лекарственного патоморфоза шизоф-рении//Вопросы психофармакологии. – М., 1976, с. 5-17.
  2. Авруцкий Г. Я. Изменение клиники и течения психозов в итоге массовой психофармакотерапии и их значение для совершенствования лечебной помощи//Журнал невропатологии и психиатрии им. С. С. Корсакова, 1979, Т. 79, вып. 9, с. 1387-1394.
  3. Аддингтон Д. Депрессия при шизофрении//Социальная и клиническая психиатрия 2006, Т. 16, вып. 2, с. 5-9.
  4. Андрусенко М.П., Морозова М. А. Комбинированное использование антидепрессантов и нейролептиков при аффективных расстройствах и шизофрении: показания к назначению, побочные эффекты и осложнения//Психиатрия и психофармакотерапия. Том 3, № 1,2001.
  5. Гурович И. Я., Зайцев С. Г. Об одной из сторон лекарственного патоморфоза периодической шизофрении//Вопросы психофармакологии, М, 1976, с. 26-36.
  6. Капилетти С. Г., Цукарзи Э. Э., Мосолов С. Н. Транскраниальная магнитная стимуляция при терапии резистентных депрессий//Психиатрия на рубеже тысячелетий//Материалы конференции. Ростов-на-Дону, 1999, с. 198-201.
  7. Магалиф А.Ю. К проблеме лекарственного патоморфоза параноидной шизофрении// Вопросы психофармакологии, М., 1976, с. 45-57.
  8. Мазо Г. Э. Влияние депрессии на течение шизофрении//Психиатрия и психофармакотерапия, Том 8, № 3,2006, с. 22-24.
  9. Мосолов С. II. Клиническое применение современных антидепрессантов. – СПб.: Медицинское информационное агентство, 1995, с. 209-352.
  10. Мосолов С. Н., Миссионжник Э. Ю., Шаров А. И. Применение дофаминстимулирующей терапии у резистентных к антидепрессантам больных эндогенными депрессиями//Социальная и клиническая психиатрия, 1993, Том 4, с. 76-82.
  11. Мосолов С.Н. Основы психофармакотерапии, М.: «Восток», 1996.
  12. Мрыхин В. В., Шуркова И. Н. Опыт применения инфракрасного лазерного воздействия для преодаления фармакорезистентности эндогенных депрессий//Материалы всероссийской научно-практической конференции «Количественная ЭЭГ и нейротерапия», С.-П6., 2007, с. 139.
  13. Орлов В. М. Место ЭСТ в психофармакотерапии периодичекской шизофрении// Вопросы психофармакологии, М., 1976. с. 106-113.
  14. Сайкин М. А. Применение внутривенного лазерного облучения крови в комплексном лечении резистентных к психофармакотерапии больных шизофренией//Диссертация на соискание ученой степени кандидата медицинских наук, М., 2002.
  15. Смулевич А. Б. К вопросу о депрессивных состояниях, возникающих в период лечения нейролептическими средствами. Журнал невропатологии и психиатрии им. С. С. Корсакова, 1961, Т. 61, вып. 2, с. 236-245.
  16. Смулевич А. Б. Психопатология и клиника депрессий, развивающихся при шизо фре-нии//Психиатрия и психофармакотерапия, 2003, Том 5.
  17. Смулевич А. Б. Депрессии при соматических и психических заболеваниях. М., 2003.
  18. Снежневский А. В. Шизофрения клиника и патогенез М., 1969.
  19. Хмелевский Д. Л. Особенности клиники и течения параноидной шизофрении в условиях непрерывной многолетней терапии нейролептиками//Вопросы психофармакологии, М., 1976. с. 82-94.
  20. Цукарзи Э. Э. Клиника и терапия затяжных депрессивных и депрессивно-бредовых состояний у больных шизоаффективным психозом (рекуррентной шизофренией)// Диссертация на соискание ученой степени кандидата медицинских наук. М., 1996.
  21. Цукарзи Э.Э., Мосолов С.Н. Дифференцированная терапия постпсихотических депрессий и депрессивно-бредовых состояний у больных шизоаффективным психозом// Аффективные и шизоаффективные психозы, М., 1998, с. 395-403.
  22. Addington DE, Addington JM.: Attempted suicide and depression in schizophrenia//Acta Psychiatr Scand., 1992, Vol. 85 (4), p. 288-291.
  23. Addington D., Addington J., Maticka-Tyndale E: Reliability and validity of depression rating scale for schizophrenics. A structured interview guide for the Hamilton Depression Rating Scale. Schizophrenia Res., 1992, Vol. 6, p. 201-208.
  24. Amore M. Pharmacological treatment of delusional depression//Minerva Psichiatr. 1996 Mar, Vol. 37, № 1, p. 29-33.
  25. Andreasen NC, Olsen S: Negative v positive schizophrenia: definition and validation. Arch. Gen. Psychiatry, 1982, Vol. 39 p. 789-794.
  26. Atre-Vaidya N, Taylor MA: Effectiveness of lithium in schizophrenia: do we really have an answer?//J. Clin. Psychiatry, 1989, Vol. 50, p. 170-173.
  27. Avari J, Mahgoub N, Alexopoulos GS: Adding aripiprazole to clozapine worsened delusions and hallucinations: a case report//J. Clin. Psychopharmacol. 2011 Aug, Vol. 31, № 4, p. 528-531.
  28. Barnes TR, Curson DA, Liddle PF, Patel M: The nature and prevalence of depression in chronic schizophrenic in-patients. Br. J. Psychiatry, 1989, Vol. 154; p. 486-491.
  29. Bartels SJ, Drake RE: Depressive symptoms in schizophrenia: comprehensive differential diagnosis//Compr. Psychiatry. 1988 Sep-Oct, Vol. 29 (5); p. 467-83.
  30. Bermanzohn PC, Siris SG: Akinesia: a syndrome common to parkinsonism, retarded depression, and negative symptoms. Compr Psychiatry 1992, Vol. 33; p. 221-232.
  31. Berrios GE, Bulbena A: Post psychotic depression: the Fulbourn cohort. Acta Psychiatr. Scand. 1987, Vol. 76; p. 89-93.
  32. Birchwood M, Mason R, Macmillan F, Healy J: Depression, demoralization and control over psychotic illness: a comparison of depressed and non-depressed patients with a chronic psychosis// Psychol. Med., 1993, Vol. 23, p. 387-395.
  33. Blackwood DH et al.: Are some genetic risk factors common to schizophrenia, bipolar disorder and depression? Evidence from DISCI, GRIK4 and NRG1. Neurotox Res. 2007 Jan, Vol. 11(1), p. 73-83.
  34. Bodkin AJ, Cohen BM, Salomon MS, Cannon SE, Zornberg GL, Cole JO: Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication//J. Nerv. Ment. Dis., 1996, Vol. 184, p. 295-301.
  35. Bressan RA et al.: Depressive episodes in stable schizophrenia: critical evaluation of the DSM-IV and ICD-10 diagnostic criteria. Psychiatry Res. 2003 Jan 25, Vol. 117 (1); p. 47-56.
  36. Bucci L: The negative symptoms of schizophrenia and the monoamine oxidase inhibitors// Psychopharmacology (Berl) 1987, Vol. 91, p. 104-108.
  37. Carpenter W.T. Jr., Heinrichs D.W., Alphs L.D.: Treatment of negative symptoms. Schizophr Bull., 1985, Vol. 11; p. 440-452.
  38. Citrome L: Role of sublingual asenapine in treatment of schizophrenia//Neuropsychiatr Dis Treat. 2011, Vol. 7, p. 325-339.
  39. Christison GW, Kirch DG, Wyatt RJ: When symptoms persist: choosing among alternative somatic treatments for schizophrenia//Schizophr Bull., 1991, Vol. 17, p. 217-240.
  40. Cohen E et al. Repetitive transcranial magnetic stimulation in treatment of chronic negative schizophrenic: a pilot study//J. Neurol. Neurosurg. Psychiatry 1999, Vol. 67, p. 129-130.
  41. Davis KL, Kahn RS, Ко G, Davidson M: Dopamine in schizophrenia: a review and reconceptualization//Am. J. Psychiatry 1991, Vol. 148; p. 1474-1486.
  42. de Figueiredo JM: Demoralization and Psychotherapy: A Tribute to Jerome D. Frank, MD, PhD (1909-2005)//Psychother Psychosom. 2007, Vol. 76 (3), p.129-33.
  43. Dilsaver SC, Coffman JA: Cholinergic hypothesis of depression: a reappraisal//J. Clin. Psychopharmacol 1989, Vol. 9, p. 173-179.
  44. Dollfus S: Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline//Evid Based Ment Health. 2011 Aug, Vol. 14, N9 3, p.79.
  45. Drake RE, Ehrlich J: Suicide attempts associated with akathisia//Am. J. Psychiatry 1985, Vol. 142; p. 499-501.
  46. Evins AE et al.: A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia//J. Clin. Psychopharmacol. 2005 Jun, Vol. 25, N2 3, p. 218-225.
  47. Evins AE, Goff DC: Adjunctive antidepressant drug therapies in the treatment of negative symptoms of schizophrenia//Drug Therapy 1996, Vol. 6, p. 130-147.
  48. Faraone SV et al.: Diagnostic accuracy and confusability analyses: an application to the Diagnostic Interview for Genetic Studies//Psychol Med 1996, Vol. 26; p.401-410.
  49. Fleischhacker WW, Roth SD, Kane JM: The pharmacologic treatment of neuroleptic-induced akathisia//J. Clin. Psychopharmacol 1990, Vol. 10, p.12-21.
  50. Fr&nberg О et al.: Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms// Psychopharmacology (Berl). 2009 Jun, Vol. 204, № 2, p.251-264.
  51. Halstead SM, Barnes TRE, Speller JC: Akathisia: prevalence and associated dysphoria in an in-patient population with chronic schizophrenia//Br. J. Psychiatry 1994, Vol. 164; p. 177—183.
  52. Hamilton M: A rating scale for depression. A structured interview guide for the Hamilton Depression Rating Scale//J. Neurol. Neurosurg. Psychiatry; 1960, Vol. 23; p. 56-62.
  53. Hamilton M: Development of a rating for primary depressive illness. A structured interview guide for the Hamilton Depression Rating Scale//Br.J. Soc. Clin. Psychol.; 1967, Vol. 6. p. 278-296.
  54. Harrow M, Yonan CA, Sands JR, Marengo J: Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved?//Schizophr Bull., 1994, Vol. 20; p. 327-338.
  55. Herz MI, Melville C. Relapse in schizophrenia//Am. J. Psychiatry. 1980 Jul, Vol. 137 (7); p. 801-805.
  56. 56.Hirsch SR, Jolley AG, Barnes TRE, Liddle PF, Curson DA, Patel A, York A, Bercu S, Patel M: Dysphoric and depressive symptoms in chronic schizophrenia//Schizophr Res 1989, Vol. 2; p. 83.
  57. Hogarty GE et al.: Pharmacotherapy of impaired affect in recovering schizophrenic patients// Arch. Gen. Psychiatry 1995, Vol. 52, p. 29-41.
  58. Janicak PG, Rado JT: Quetiapine monotherapy for bipolar depression//Expert Opin Pharmacother. 2011 Jul, Vol. 12, № 10, p. 1643-1651.
  59. Johnson DAW: The significance of depression in the prediction of relapse in chronic schizophrenia//Br. J. Psychiatry 1988, Vol. 152; p. 320-323.
  60. Jones H: Risperidone: a review of its pharmacology and use in the treatment of schizophrenia//J Serotonin Res 1997, Vol. 4, p.17-28.
  61. Kasckow J. et al.: Suicidality in middle aged and older patients with schizophrenia and depressive symptoms: relationship to functioning and Quality of Life//Int J Geriatr Psychiatry. 2007, May 15.
  62. Kibel D.A., Laffont I., Liddle P.F.: The composition of the negative syndrome of chronic schizophrenia. Br. J. Psychiatry 1993, Vol. 162; p. 744-750.
  63. Kim SW et al.: Diagnostic validity of assessment scales for depression in patients with schizophrenia. Psychiatry Res. 2006 Aug 9.
  64. Kirli S, Caliskan M: A comparative study of sertraline versus imipramine in postpsychotic depressive-disorder of schizophrenia//Schizophr Res. 1998 Sep 7, Vol. 33, № 1-2, p.103-111.
  65. Knights A, Hirsch SR: «Revealed» depression and drug treatment for schizophrenia//Arch. Gen. Psychiatry 1981, Vol. 38; p.806-811.
  66. Kudo J, Mori H, Gomibuchi T: Loneliness as expressed by schizophrenic patients in the early remission phase//Nagoya J Med Sci. 2002 Nov, Vol. 65 (3-4); p.l 15-126.
  67. Kuck J, Zisook S, Moranville JT, Heaton RK, Raff DL: Negative symptomatology in schizophrenic outpatients//J Nerv Ment Dis 1992, Vol. 180; p.510-515.
  68. Lerner Y, Mintzer Y, Schestatzky M: Lithium combined with haloperidol in schizophrenic patients//Br. J. Psychiatry 1988, Vol. 153, p.359-362.
  69. Levinson DF, Umapathy C, Musthaq M: Treatment of schizoaffective disorder and schizophrenia with mood symptoms//Am. J. Psychiatry 1999, Vol. 156, p.l 138-1148.
  70. Liemburg E, Aleman A, Bous J, Hollander K, Knegtering H: An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well-being// Pharmacopsychiatry. 2011 May, Vol. 44, № 3, p.109-113.
  71. Lindenmayer J.P., Grochowski S., Kay SR: Schizophrenic patients with depression: psychopathological profiles and relationship with negative symptoms//Compr Psychiatry 1991, Vol. 32; p. 528-533.
  72. Maggini C, Raballo A: Exploring depression in schizophrenia//Eur Psychiatry. 2006 Jun, Vol. 21 (4), p. 227-32.
  73. Malla AK, Norman RMG: Prodromal symptoms in schizophrenia//Br. J. Psychiatry 1994, Vol. 164; p. 287-293.
  74. Mandel MR, Severe JB, Schooler NR, Gelenberg AJ, Mieske M: Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics//Arch. Gen. Psychiatry 1982, Vol. 39; p. 197-203.
  75. Martin RL, Cloninger CR, Guze SB, Clayton PJ: Frequency and differential diagnosis of depressive syndromes in schizophrenia//J. Clin. Psychiatry 1985, Vol. 46; p. 9-13.
  76. Mazeh D, Melamed Y, Elizur A: Venlafaxine in the treatment of resistant postpsychotic depressive symptoms of schizophrenia//J. Clin. Psychopharmacol. 1999 Jun; 19 (3): p. 284-285.
  77. McGlashan TH, Carpenter W.J. Jr.: Postpsychotic depression in schizophrenia//Arch. Gen. Psychiatry 1976, Vol. 33; p. 231-239.
  78. Meltzer HY et al.: Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)//Arch. Gen. Psychiatry. 2003 Jan, Vol. 60 (1), p. 82-91.
  79. Micallef J, Fakra E, Blin O: Use of antidepressant drugs in schizophrenic patients with depression. Encephale. 2006 Mar-Apr, Vol. 32 (2 Pt 1), p. 9-263.
  80. Mulholland C., Cooper S.* The symptom of depression in schizophrenia and its management. Advances in Psychiatric Treatment 2000, Vol. 6, p. 169-177.
  81. 81.Mulholland C et al.: A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia//J Psychopharmacol. 2003 Mar, Vol. 17, №l,p. 107-112.
  82. Mulholland et al.: A double-blind, placebo-controlled trial of sertraline for depressive symptoms in stable, chronic schizophrenia//Biological Psychiatry. 1997, Vol. 42, p. 15.
  83. Muller MJ, Muller KM, Fellgiebel A: Detection of depression in acute schizophrenia: sensitivity and specificity of 2 standard observer rating scales//Can. J. Psychiatry. 2006 May, Vol. 51(6); p. 387-92.
  84. Nahas Z. et al. Could left prefrontal rTMS modify negative symptoms and attention in schizophrenia?//Biol. Psychiatry 1999; 45; 37S.
  85. Narvaez JM.: Subjective and objective quality of life in schizophrenia//Schizophr Res. 2007 Oct 3.
  86. Noordsy DL, Green Al: Pharmacotherapy for schizophrenia and co-occurring substance use disorders//Curr Psychiatry Rep. 2003 Oct, Vol. 5, № 5, p. 340-346.
  87. Norholm V, Bech R: Quality of life in schizophrenic patients: association with depressive symptoms//Nord J Psychiatry. 2006, Vol. 60 (1); p. 32-769.
  88. Norman RMG, Malla AK: Dysphoric mood and symptomatology in schizophrenia//Psychol Med 1991, Vol. 21; p. 897-903.
  89. Perenyi A, Goswami U, Frecska E, Arato M: L-Deprenyl in treating negative symptoms of schizophrenia//Psychiatry Res 1992, Vol. 42, p. 189-191.
  90. Philip NS, Carpenter L.L., Tyrka AR, Price LH: Augmentation of antidepressants with atypical antipsychotics: a review of the current literature//J Psychiatr Pract. 2008 Jan, Vol 14, № 1, p. 34-44.
  91. Plasky P: Antidepressant usage in schizophrenia//Schizophr Bull., 1991, Vol. 17, p. 649-657.
  92. Prikryl R et al. Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double-blind, randomized controlled study//Schizophrenia Research, 2007, Vol. 95, p. 151-157.
  93. RollnikJ.D. et al. High frequency repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex in schizophrenic patients//Neuroreport 2000, Vol. 11, № 18, p. 4013-4015.
  94. A, Thompson R, Kennedy S: Depression in chronic schizophrenia//Br. J. Psychiatry 1983, Vol. 142, p. 465-470.
  95. Roy A: Do neuroleptics cause depression?//Biol Psychiatry 1984, Vol. 19, p. 777-781
  96. Roy A: Suicide in chronic schizophrenia//Br. J. Psychiatry. 1982 Aug; 141:171-7.
  97. Roy A: Risk factors for suicide in psychiatric patients//Arch. Gen. Psychiatry. 1982 Sep, Vol. 39, №9, p. 1089-1095.
  98. Sanford M: Quetiapine extended release: adjunctive treatment in major depressive disorder// CNS Drugs. 2011 Sep 1, Vol. 25, № 9, p. 803-813.
  99. Sepehry AA et al.: Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis//J. Clin. Psychiatry. 2007 Apr, Vol. 68, № 4, p. 604-610.
  100. Shear K, Frances A, Weiden P: Suicide associated with akathisia and depot fluphenazine treatment//J. Clin. Psychopharmacol 1983, Vol. 3; p.235-236.
  101. Simons W, Dierick M. Transcranial magnetic stimulation as a therapeutic tool in psychiatry//The World Journal of Biological Psychiatry, 2005, Vol. 6, № 1, p. 6-25.
  102. Simms J et al.: Correlates of self-harm behaviour in acutely ill patients with schizophrenia// Psychol Psychother. 2007 Mar, Vol. 80 (Pt 1); p. 39-49.
  103. Siris SG: Diagnosis of secondary depression in schizophrenia, implications for DSM-IV// Schizophr Bull., 1991, Vol. 17; p. 75-98.
  104. Siris SG.: Depression in Schizophrenia: Perspective in the Era of «Atypical» Antipsychotic Agents//Am. J. Psychiatry. 2000 Sep, Vol. 157; p. 1379-1389.
  105. Siris SG, Strahan A, Mandeli J, Cooper ТВ, Casey E: Fluphenazine decanoate dose and severity of depression in patients with post-psychotic depression//Schizophr Res 1988, Vol. 1, p. 31-35.
  106. Siris SG: Depression and schizophrenia, in Schizophrenia. Edited by Hirsch SR, Weinberger DR//Cambridge, Mass, Blackwell Science, 1995, p. 128-145.
  107. Siris SG et al.: Adjunctive imipramine in the treatment of post-psychotic depression: a controlled trial//Arch. Gen. Psychiatry 1987, Vol. 44, p. 533-539.
  108. Siris SG et al.: Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial//Arch. Gen. Psychiatry. 1994 Feb, Vol. 51, № 2, p. 109-115.
  109. Siris SG, Rifkin AE, Reardon GT: Response of postpsychotic depression to adjunctive imipramine or amitriptyline//J. Clin. Psychiatry. 1982 Dec, Vol. 43, № 12, p.485-486.
  110. Siris SG et al: The use of antidepressants for negative symptoms in a subset of schizophrenic patients//Psychopharmacol Bull., 1991, Vol. 27, № 3, p. 331-335.
  111. Siris SG, Adan F, Cohen M, Mandeli J, Aronson A, Casey E: Postpsychotic depression and negative symptoms: an investigation of syndromal overlap//Am. J. Psychiatry 1988, Vol. 145; p. 1532-1537.
  112. Stip E, Tourjman V: Aripiprazole in schizophrenia and schizoaffective disorder://A review. Clin Ther. 2010, Vol. 32, Suppl. 1, S3-20.
  113. Tandon R, Greden JF: Cholinergic hyperactivity and negative schizophrenic symptoms// Arch. Gen. Psychiatry 1989, Vol. 46, p. 745-753.
  114. Tarsy D, Baldessarini RJ, Tarazi FI: Effects of newer antipsychotics on extrapyramidal function//CNS Drugs. 2002, Vol. 16, № 1, p. 23-45.
  115. Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia//Cochrane Database Syst Rev. 2002, № 2, CD000076.
  116. M. et al.: Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies//J. Clin. Psychiatry. 2010 Apr, Vol. 71, № 4, p. 451-462.
  117. Tollefson GD, Andersen SW, Tran PV: The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone// Biol Psychiatry 1999, Vol. 46, p. 365-373.
  118. Van Putten T, May PR A: «Akinetic depression» in schizophrenia//Arch. Gen. Psychiatry 1978, Vol. 35; p.1101-1107.
  119. Van Putten T: The many faces of akathisia. Compr. Psychiatry 1975, Vol. 16, p. 43-47.
  120. Weiden PJ: EPS profiles: the atypical antipsychotics are not all the same//J. Psychiatr. Pract., 2007 Jan, Vol. 13, № 1, p.13-24.
  121. Wise RA: Neuroleptics and operant behaviour: the anhedonia hypothesis. Behav Brain Sci 1982, Vol. 5; p.39-87.
  122. Yacubian J et al.: Subregions of the ventral striatum show preferential coding of reward mag nitude and probability//Neuroimage,2007 Aug 22.
  123. Zink M: Duloxetine treatment of major depressive episodes in the course of psychotic disorders//Pharmacopsychiatry. 2006 May, Vol. 39, № 3, p. 109-111.

Если вы нашли ошибку, пожалуйста, выделите фрагмент текста и нажмите Ctrl+Enter.